Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: May 23, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | May 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on 5/23, check the press release for deets.
AI Summary
Innate Pharma SA filed a Form 6-K on May 23, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is making a public announcement, which could contain material information for investors. Investors should review the referenced press release for details.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, without providing new financial data within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- May 23, 2025 (date) — Filing and Press Release Date
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report a press release dated May 23, 2025, by Innate Pharma SA to the U.S. Securities and Exchange Commission.
What is the filing date of this report?
The filing date of this report is May 23, 2025.
Does this filing include an annual report?
No, this filing indicates that Innate Pharma SA files annual reports under cover of Form 20-F, not this Form 6-K.
What is the principal executive office address of Innate Pharma SA?
The principal executive office address of Innate Pharma SA is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is attached to this Form 6-K?
Exhibit 99.1, a Press Release dated May 23, 2025, is attached to this Form 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 23, 2025 regarding Innate Pharma SA (IPHYF).